Detalles de la búsqueda
1.
Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants.
Antimicrob Agents Chemother
; 68(1): e0078123, 2024 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38038460
2.
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Clin Infect Dis
; 77(10): 1423-1431, 2023 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37340869
3.
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Clin Infect Dis
; 76(9): 1646-1654, 2023 05 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36660819
4.
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
Lancet
; 399(10337): 1779-1789, 2022 05 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35378077
5.
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
N Engl J Med
; 382(12): 1124-1135, 2020 03 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32130806
6.
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
N Engl J Med
; 382(12): 1112-1123, 2020 03 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32130809
7.
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials.
HIV Med
; 24(5): 568-579, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36411596
8.
Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men.
Antimicrob Agents Chemother
; 66(3): e0205721, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35129374
9.
Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects.
Br J Clin Pharmacol
; 88(10): 4607-4622, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35695476
10.
Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir.
J Antimicrob Chemother
; 75(8): 2240-2248, 2020 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32361755
11.
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
PLoS Med
; 15(11): e1002690, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30408115
12.
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Lancet
; 390(10101): 1499-1510, 2017 Sep 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-28750935
13.
Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans.
Xenobiotica
; 46(2): 147-62, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26134155
14.
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
Ther Adv Infect Dis
; 10: 20499361231214626, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38107552
15.
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Lancet HIV
; 10(9): e566-e577, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37567205
16.
Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study.
Open Forum Infect Dis
; 9(4): ofac067, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35350172
17.
Sexually transmitted infections and depot medroxyprogesterone acetate do not impact protection from simian HIV acquisition by long-acting cabotegravir in macaques.
AIDS
; 36(2): 169-176, 2022 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34482355
18.
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.
AIDS
; 36(2): 195-203, 2022 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34652287
19.
Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
J Int AIDS Soc
; 25(9): e26006, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36097674
20.
Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE).
J Int AIDS Soc
; 25(9): e26003, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36094142